Ben Venue will produce the Cloretazine currently in Phase III trials.

Ben Venue Laboratories will manufacture Vion Pharmaceuticals’ Cloretazine, its lead anticancer agent, under a manufacturing agreement. 

Cloretazine, an alkylating agent, is being evaluated in a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia (AML) and a Phase II trial in elderly patients with previously untreated de novo poor-risk AML.

Previous articleIntrogen Awarded European Patent
Next articleAblynx Achieves First Milestone With P&GP